CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases

Please visit answersincme.com/FVG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the clinical impact of novel and emerging tyrosine kinase 2 (TYK2) inhibitors in the treatment of patients with plaque psoriasis who are candidates for systemic therapy. Upon completion of this activity, participants should be better able to: Identify the unmet therapeutic needs for patients with plaque psoriasis who are candidates for systemic therapy; Describe the clinical impact of novel and emerging TYK2 inhibitors in the treatment of eligible patients with plaque psoriasis; and Outline strategies to optimize outcomes for patients with plaque psoriasis who may be candidates for systemic treatment with a TYK2 inhibitor.

Please visit answersincme.com/QWR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the evidence for and appropriate use of newly approved and emerging biologic therapies for the treatment of prurigo nodularis (PN). Upon completion of this activity, participants should be better able to: Recognize the rationale for investigating biologic therapies to address unmet therapeutic needs for patients with PN; Describe the clinical profiles of approved and emerging biologic therapies for the treatment of PN; and Outline approaches to optimally integrate biologic therapies into treatment plans for PN.

Please visit answersincme.com/WBE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in allergy and immunology discusses how new and emerging therapeutic options targeting type 2 inflammation can improve quality of life for patients with eosinophilic esophagitis (EoE). Upon completion of this activity, participants should be better able to: Recognize the therapeutic rationale for targeting type 2 inflammatory factors to treat EoE; and Outline individual approaches to optimize therapeutic regimens for patients with EoE.

Please visit answersincme.com/DRN860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gastroenterology discusses emerging small molecule therapies in the treatment of moderate-to-severe Crohn’s disease. Upon completion of this activity, participants should be better able to: Identify the clinical rationale for using emerging selective Janus kinase (JAK) inhibitors and sphingosine 1–phosphate (S1P) receptor modulators in Crohn’s disease; Describe evidence from late-stage clinical trials on the use of small molecule therapies in individuals with moderate-to-severe Crohn’s disease; and Outline patient-centered strategies for optimizing treatment with small molecule therapies in moderate-to-severe Crohn’s disease.

Please visit answersincme.com/NVY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pediatrics and immunology discusses the continued burden of respiratory syncytial virus (RSV) in infants and strategies to increase vaccine uptake. Upon completion of this activity, participants should be better able to: Recognize the rationale for respiratory syncytial virus (RSV) prevention in infants; Review the clinical profiles of national guideline-recommended RSV prophylactic agents in infants; and Outline patient-centered strategies to optimize the uptake of RSV prophylactic options in infants.